WO2008084504A3 - Pharmaceutical compositions of angiotensin ii receptor blockers - Google Patents

Pharmaceutical compositions of angiotensin ii receptor blockers Download PDF

Info

Publication number
WO2008084504A3
WO2008084504A3 PCT/IN2008/000017 IN2008000017W WO2008084504A3 WO 2008084504 A3 WO2008084504 A3 WO 2008084504A3 IN 2008000017 W IN2008000017 W IN 2008000017W WO 2008084504 A3 WO2008084504 A3 WO 2008084504A3
Authority
WO
WIPO (PCT)
Prior art keywords
absorption
present
arb
angiotensin
release
Prior art date
Application number
PCT/IN2008/000017
Other languages
French (fr)
Other versions
WO2008084504A2 (en
Inventor
Pratibha S Pilgaonkar
Maharukh T Rustomjee
Anilkumar S Gandhi
Nagesh R Palepu
Original Assignee
Rubicon Res Private Ltd
Pratibha S Pilgaonkar
Maharukh T Rustomjee
Anilkumar S Gandhi
Nagesh R Palepu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubicon Res Private Ltd, Pratibha S Pilgaonkar, Maharukh T Rustomjee, Anilkumar S Gandhi, Nagesh R Palepu filed Critical Rubicon Res Private Ltd
Publication of WO2008084504A2 publication Critical patent/WO2008084504A2/en
Publication of WO2008084504A3 publication Critical patent/WO2008084504A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the methods of increasing the bioavailability of Angiotensin II Receptor Blockers (ARBs) by treating it with at least one absorption augmenting agent. In particular, the present invention relates to use of absorption augmenting agents which results in significant increase in the bioavailability as more drug is present in the absorbable form at the absorption site which is in sharp contrast to the currently marketed ARB formulations. In the composition, the ARB may be present in the form of physical blend, solid dispersion, solid solution or complex with absorption augmenting agent. The composition of an ARB with absorption augmenting agent can be incorporated in a tablet, coated tablet, inlay or bilayer tablet or capsule dosage form for immediate release, sustained release, pulsatile release or modified release.
PCT/IN2008/000017 2007-01-12 2008-01-11 Pharmaceutical compositions of angiotensin ii receptor blockers WO2008084504A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN66MU2007 2007-01-12
IN66/MUM/2007 2007-01-12

Publications (2)

Publication Number Publication Date
WO2008084504A2 WO2008084504A2 (en) 2008-07-17
WO2008084504A3 true WO2008084504A3 (en) 2009-07-23

Family

ID=39493604

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000017 WO2008084504A2 (en) 2007-01-12 2008-01-11 Pharmaceutical compositions of angiotensin ii receptor blockers

Country Status (1)

Country Link
WO (1) WO2008084504A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278909A1 (en) * 2007-06-06 2010-11-04 Dexcel Ltd. Process for forming solid oral dosage forms of angiotensin ii receptor antagonists
WO2009017812A2 (en) * 2007-08-01 2009-02-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of candesartan
WO2009084040A1 (en) * 2007-12-28 2009-07-09 Rubicon Research Private Limited Once a day formulation of angiotensin receptor blockers
US20110028526A1 (en) * 2008-02-28 2011-02-03 Amol Matharu Valsartan solid oral dosage forms and methods of making such formulations
MX2010013238A (en) * 2008-06-03 2010-12-21 Novartis Ag Pulsatile release of valsartan.
UA108742C2 (en) 2009-09-23 2015-06-10 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED DISEASES
CN103040777B (en) * 2012-12-17 2014-09-10 海南圣欣医药科技有限公司 Olmesartan ester liposome solid preparation
WO2016005994A2 (en) * 2014-07-06 2016-01-14 Gattefosse India Pvt. Ltd. Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
CN107095862B (en) * 2017-06-27 2018-05-15 乐普恒久远药业有限公司 A kind of valsartan capsule and preparation method thereof
EP3694488A4 (en) 2017-10-13 2021-07-07 Research Triangle Institute Hydroxychloroquine sulfate formulations and methods for preparation and use thereof
CN112569241B (en) * 2019-09-27 2021-11-02 武汉武药科技有限公司 Telmisartan and hydrochlorothiazide double-layer tablet and preparation method thereof
EP4295839A1 (en) * 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1346722A1 (en) * 2000-12-01 2003-09-24 Takeda Chemical Industries, Ltd. Method for producing preparation containing bioactive substance
WO2005070398A2 (en) * 2004-01-23 2005-08-04 Ranbaxy Laboratories Limited Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
WO2005079751A2 (en) * 2004-01-23 2005-09-01 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of candesartan cilexetil
US20060165806A1 (en) * 2005-01-06 2006-07-27 Elan Pharma International Limited Nanoparticulate candesartan formulations
WO2006113631A2 (en) * 2005-04-18 2006-10-26 Rubicon Research Pvt. Ltd. Bioenhanced compositions
WO2007077581A2 (en) * 2006-01-02 2007-07-12 Rubicon Research Private Limited Pharmaceutical compositions
WO2008045006A1 (en) * 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1346722A1 (en) * 2000-12-01 2003-09-24 Takeda Chemical Industries, Ltd. Method for producing preparation containing bioactive substance
WO2005070398A2 (en) * 2004-01-23 2005-08-04 Ranbaxy Laboratories Limited Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
WO2005079751A2 (en) * 2004-01-23 2005-09-01 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of candesartan cilexetil
US20060165806A1 (en) * 2005-01-06 2006-07-27 Elan Pharma International Limited Nanoparticulate candesartan formulations
WO2006113631A2 (en) * 2005-04-18 2006-10-26 Rubicon Research Pvt. Ltd. Bioenhanced compositions
WO2007077581A2 (en) * 2006-01-02 2007-07-12 Rubicon Research Private Limited Pharmaceutical compositions
WO2008045006A1 (en) * 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan

Also Published As

Publication number Publication date
WO2008084504A2 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
WO2008084504A3 (en) Pharmaceutical compositions of angiotensin ii receptor blockers
WO2011116139A3 (en) Improved pharmaceutical compositions comprising cck- 8 and methods of delivery
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
AR075735A1 (en) PHARMACEUTICAL COMPOSITIONS OF IMMEDIATE RELEASE THAT INCLUDE OXYCODONE AND NALOXONE. USE
EA201100691A1 (en) ANTAGONISTS OF LYSOPHPATIDIC ACID RECEPTORS
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
EA201100313A1 (en) METHOD OF DELIVERY OF THE PHARMACEUTICAL COMPOSITION TO THE PATIENT NEEDING THIS
NZ590291A (en) Pharmaceutical compositions for treatment of parkinson's disease
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
MX2020011961A (en) Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances.
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
WO2012032209A3 (en) Pharmaceutical composition for the treatment of dry eye
MX2011012122A (en) Thiophene derivatives.
WO2011157416A3 (en) Transdermal administration of memantine
MY156288A (en) Pharmaceutical formulations containing dopamine receptor ligands.
JO2973B1 (en) Fumarate Salt Of (alphaS, betaR)-6-Bromo-alfa-[2-(dimethylamino)ethyl]-2- Methoxy-alpha-1-naphthalenyl-beta-phenyl-3- Quinolineethanol
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
WO2011081493A3 (en) Pharmaceutical composition comprising metformin and rosuvastatin
AR082312A1 (en) A PHARMACEUTICAL COMBINATION COMPOSITION TO TREAT DIABETES AND METABOLIC DISORDERS
WO2010092450A8 (en) Stable pharmaceutical composition for atherosclerosis
IL215826A (en) Sustained release pharmaceutical composition, process for its preparation, its use for the manufacture of a medicament for the treatment of pain and a tablet comprising it
MX344846B (en) Combination of active loaded granules with additional actives.
PH12015500823A1 (en) Modified release formulations for oprozomib
WO2010031521A3 (en) Pancreatic polypeptide and variants thereof for use in the treatment of intestinal disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08720084

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08720084

Country of ref document: EP

Kind code of ref document: A2